1691 related articles for article (PubMed ID: 24566842)
21. Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: a systematic review.
Boehncke WH; Alvarez Martinez D; Solomon JA; Gottlieb AB
J Rheumatol; 2014 Nov; 41(11):2301-5. PubMed ID: 25362715
[TBL] [Abstract][Full Text] [Related]
22. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.
Yang H; Craig D; Epstein D; Bojke L; Light K; Bruce IN; Sculpher M; Woolacott N
Pharmacoeconomics; 2012 Apr; 30(4):257-70. PubMed ID: 22283690
[TBL] [Abstract][Full Text] [Related]
23. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.
Weger W
Br J Pharmacol; 2010 Jun; 160(4):810-20. PubMed ID: 20590580
[TBL] [Abstract][Full Text] [Related]
24. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
25. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis.
Galadari H; Fuchs B; Lebwohl M
Int J Dermatol; 2003 Mar; 42(3):231-7. PubMed ID: 12653923
[TBL] [Abstract][Full Text] [Related]
26. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
Hamilton TK
J Drugs Dermatol; 2008 Nov; 7(11):1089-93. PubMed ID: 19110745
[TBL] [Abstract][Full Text] [Related]
27. Cyclosporine in psoriatic arthropathy.
Soriano A; Pipitone N; Salvarani C
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S101-3. PubMed ID: 26470797
[TBL] [Abstract][Full Text] [Related]
28. [Biologics in the treatment of psoriasis].
Dissemond J; Grabbe S
MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
[TBL] [Abstract][Full Text] [Related]
29. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study.
Sfikakis PP; Vassilopoulos D; Katsifis G; Vosvotekas G; Dimitroulas T; Sidiropoulos P; Vounotrypidis P; Bogdanos DP; Georgountzos AΙ; Bounas AG; Georgiou P; Gazi S; Kataxaki E; Liossis SN; Theodorou E; Papagoras C; Theotikos E; Vlachoyiannopoulos P; Voulgari PV; Kekki A; Antonakopoulos N; Boumpas DT
Rheumatol Int; 2023 May; 43(5):889-902. PubMed ID: 36856816
[TBL] [Abstract][Full Text] [Related]
30. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
[TBL] [Abstract][Full Text] [Related]
31. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.
Papoutsaki M; Costanzo A; Chimenti MS; Chimenti S
Expert Opin Biol Ther; 2008 Mar; 8(3):363-70. PubMed ID: 18294106
[TBL] [Abstract][Full Text] [Related]
32. New targets in psoriatic arthritis.
Braun J
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii30-ii37. PubMed ID: 27856658
[TBL] [Abstract][Full Text] [Related]
33. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
Gandjour A; Ostwald DA
Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
[TBL] [Abstract][Full Text] [Related]
34. Golimumab for the treatment of psoriatic arthritis.
Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
[TBL] [Abstract][Full Text] [Related]
35. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
36. Treatment recommendations for psoriatic arthritis.
Ritchlin CT; Kavanaugh A; Gladman DD; Mease PJ; Helliwell P; Boehncke WH; de Vlam K; Fiorentino D; Fitzgerald O; Gottlieb AB; McHugh NJ; Nash P; Qureshi AA; Soriano ER; Taylor WJ;
Ann Rheum Dis; 2009 Sep; 68(9):1387-94. PubMed ID: 18952643
[TBL] [Abstract][Full Text] [Related]
37. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
van de Kerkhof PC; Reich K; Kavanaugh A; Bachelez H; Barker J; Girolomoni G; Langley RG; Paul CF; Puig L; Lebwohl MG
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2002-10. PubMed ID: 25885420
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
[TBL] [Abstract][Full Text] [Related]
39. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
40. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
